MedPath

Human Papillomavirus Genotyping is a Reliable Prognostic Marker of Recurrence for High-Grade Cervical Intraepithelial Neoplasia (CIN2-3) with Positive Margins after Loop Electrosurgical Excision Procedure

Not Applicable
Recruiting
Conditions
Neoplasms
Registration Number
KCT0005593
Lead Sponsor
Chonnam National University Hospital Hwasun Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
181
Inclusion Criteria

(1) pathologically confirmed CIN2-3 by a LEEP;
(2) patients with both pre- and post-LEEP HR HPV test results from the hybrid capture II assay (HC2) (Digene Co, Gaithersburg, MD) and the HDC test; and
(3) women who received follow-up examinations for = 5 years.

Exclusion Criteria

patients with a residual CIN2-3 lesion that was confirmed within three months following the LEEP.

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HPV test
Secondary Outcome Measures
NameTimeMethod
cytology
© Copyright 2025. All Rights Reserved by MedPath